

References: The Role of Aberrant Cytokine Activity in the Host Immune Response to COVID-19 Webinar



Bio-Plex Multiplex Immunoassays

Bulletin 7391

References

Abe J. Cytokines in Kawasaki disease (Japanese). *Nihon Rinsho*. 2014 Sep;72(9):1548-53.

PMID: [25518401](#)

Becker RC. COVID-19 update: Covid-19-associated coagulopathy. *J Thromb Thrombolysis*. 2020;1-14. DOI: [10.1007/s11239-020-02134-3](#)

Califano D, Furuya Y, Roberts S, et al. IFN- γ increases susceptibility to influenza A infection through suppression of group II innate lymphoid cells. *Mucosal Immunol*. 2018;11:209–219. DOI: [10.1038/mi.2017.41](#)

Chaolin Huang, Yeming Wang, Xingwant Li, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. *The Lancet* 2020;395(10223):497-506. DOI: [10.1016/S0140-6736\(20\)30183-5](#)

Chang LY, Lu CY, Shao PL, et al. Viral infections associated with Kawasaki disease. *J Formos Med Assoc*. 2014;113(3):148-154. DOI: [10.1016/j.jfma.2013.12.008](#)

Chien, JY, et al. Temporal changes in cytokine/chemokine profiles and pulmonary involvement in severe acute respiratory syndrome. *Respirology* 2006;11(6):715-722. DOI: [10.1111/j.1440-1843.2006.00942.x](#)

Choy EH, Jones SA, Aletaha D, et al. IL-6: To immunity and beyond. *Considerations in Medicine* 2018;2: DOI: [10.1136/conmed-2018-000004](#)

De Miguel C, Rudemiller NP, Abais JM, Mattson DL. Inflammation and hypertension: new understandings and potential therapeutic targets. *Curr Hypertens Rep*. 2015;17(1):507. DOI: [10.1007/s11906-014-0507-z](#)

Feghali CA, Wright TM. Cytokines in acute and chronic inflammation. *Front Biosci*. 1997;2:d12-d26. DOI: [10.2741/a171](#)

Gabay C. Interleukin-6 and chronic inflammation. *Arthritis Res Ther*. 2006;8(Suppl 2):S3. DOI: [10.1186/ar1917](#)

Hasan, KS, Mandeep, RM. COVID-19 illness in native and immunosuppressed states: A clinical–therapeutic staging proposal, *The Journal of Heart and Lung Transplantation* 2020;39(5):405-407. DOI: [10.1016/j.healun.2020.03.012](#)

Hayney MS, et al. Serum IFN- γ -induced protein 10 (IP-10) as a biomarker for severity of acute respiratory infection in healthy adults. *J Clin Virol.* 2017;90:32-37. doi: [10.1016/j.jvc.2017.03.003](https://doi.org/10.1016/j.jvc.2017.03.003)

Jones SA. Directing Transition from Innate to Acquired Immunity: Defining a Role for IL-6. *The Journal of Immunology* 2005;175(6):3463-3468; DOI: [10.4049/jimmunol.175.6.3463](https://doi.org/10.4049/jimmunol.175.6.3463)

Kiers HD, et al. Immunologic Consequences of Hypoxia during Critical Illness. *Anesthesiology* 2016;125(1):237-249. DOI: [10.1097/ALN.0000000000001163](https://doi.org/10.1097/ALN.0000000000001163)

Kim ES, et al. Clinical Progression and Cytokine Profiles of Middle East Respiratory Syndrome Coronavirus Infection. *J Korean Med Sci.* 2016;31(11):1717-1725. DOI: [10.3346/jkms.2016.31.11.1717](https://doi.org/10.3346/jkms.2016.31.11.1717)

Kuba K, Imai Y, Rao S, et al. A crucial role of angiotensin converting enzyme 2 (ACE2) in SARS coronavirus-induced lung injury. *Nat Med.* 2005;11:875-879. DOI: [10.1038/nm1267](https://doi.org/10.1038/nm1267)

Lacy P, Stow JL. Cytokine release from innate immune cells: association with diverse membrane trafficking pathways. *Blood* 2011;118(1):9-18. DOI: [10.1182/blood-2010-08-265892](https://doi.org/10.1182/blood-2010-08-265892)

Lau, SKP et al. Delayed Induction of Proinflammatory cytokines and suppression of Innate Antiviral Response by the Novel Middle East Respiratory Syndrome Coronavirus: Implications for Pathogenesis and Treatment. *J Gen Virol.* 2013;94(12) DOI: [10.1099/vir.0.055533-0](https://doi.org/10.1099/vir.0.055533-0)

Lemke G, Silverman GJ. Blood clots and TAM receptor signalling in COVID-19 pathogenesis. *Nat Rev Immunol.* 2020;1-2. DOI: [10.1038/s41577-020-0354-x](https://doi.org/10.1038/s41577-020-0354-x)

Lim PW, Garssen J, Sandalova E. Potential Use of Salivary Markers for Longitudinal Monitoring of Inflammatory Immune Responses to Vaccination. *Mediators of Inflammation* 2016;6958293. DOI: [10.1155/2016/6958293](https://doi.org/10.1155/2016/6958293)

Liu J, Li S, Liu J, et al. Longitudinal characteristics of lymphocyte responses and cytokine profiles in the peripheral blood of SARS-CoV-2 infected patients. *EBioMedicine* 2020;55:102763. DOI: [10.1016/j.ebiom.2020.102763](https://doi.org/10.1016/j.ebiom.2020.102763)

Liu M, et al. CXCL10/IP-10 in infectious disease pathogenesis and potential therapeutic implications. *Cytokine Growth F R.* 2011;22: 121-130. DOI: [10.1016/j.cytogfr.2011.06.001](https://doi.org/10.1016/j.cytogfr.2011.06.001)

Metzemaekers, M, et al. Overview of the Mechanisms that May Contribute to the Non-Redundant Activities of Interferon-Inducible CXC Chemokine Receptor 3 Ligands. *Front. Immunol.* 2018;8:1970. DOI: [10.3389/fimmu.2017.01970](https://doi.org/10.3389/fimmu.2017.01970)

Mingyue Li, Yalan Dong, Haijun Wang, et al. Cardiovascular disease potentially contributes to the progression and poor prognosis of COVID-19, *Nutrition, Metabolism and Cardiovascular Diseases* 2020. DOI: [10.1016/j.numecd.2020.04.013](https://doi.org/10.1016/j.numecd.2020.04.013)

Modjarrad K. Treatment strategies for Middle East respiratory syndrome coronavirus. *J Virus Erad* . 2016;2(1):1-4; Liu Q, Zhou YH, Yang ZQ. The cytokine storm of severe influenza and development of immunomodulatory therapy. *Cell Mol Immunol*. 2016;13(1):3-10. DOI: [10.1038/cmi.2015.74](https://doi.org/10.1038/cmi.2015.74)

North American Thrombosis Forum

Rodrigues Prestes TR, Rocha NP, Miranda AS, et al. The Anti-Inflammatory Potential of ACE2/Angiotensin-(1-7)/Mas Receptor Axis: Evidence from Basic and Clinical Research. *Current Drug Targets* 2017;18:1301. DOI: [10.2174/1389450117666160727142401](https://doi.org/10.2174/1389450117666160727142401)

Salomon R, Hoffmann E, Webster RG. Inhibition of the cytokine response does not protect against lethal H5N1 influenza infection *PNAS* 2007, 104 (30) 12479-12481; DOI: [10.1073/pnas.0705289104](https://doi.org/10.1073/pnas.0705289104)

Schett G, Elewaut D, McInnes IB, Dayer JM and Neurath MF. How cytokine networks fuel inflammation: Toward a cytokine based disease taxonomy. *Nat. Med.* 2014;19:822–824. DOI: [10.1038/nm.3260](https://doi.org/10.1038/nm.3260)

Shimabukuro-Vornhagen A, Gödel P, Subklewe M, et al. Cytokine release syndrome. *J Immunother Cancer* 2018;6(1):56. DOI: [10.1186/s40425-018-0343-9](https://doi.org/10.1186/s40425-018-0343-9)

Sokol CL, Luster AD. The chemokine system in innate immunity. *Cold Spring Harb Perspect Biol*. 2015;7(5):a016303. DOI: [10.1101/cshperspect.a016303](https://doi.org/10.1101/cshperspect.a016303)

Stockman LJ, Bellamy R, Garner P. SARS: systematic review of treatment effects. *PLoS Med*. 2006;3(9):e343. DOI: [10.1371/journal.pmed.0030343](https://doi.org/10.1371/journal.pmed.0030343)

Sun X, Wang T, Cai D, et al. Cytokine storm intervention in the early stages of COVID-19 pneumonia. *Cytokine & Growth Factor Reviews* 2020. DOI: [10.1016/j.cytogfr.2020.04.002](https://doi.org/10.1016/j.cytogfr.2020.04.002)

Tanase DM, Gosav EM, Radu S, et al. Arterial Hypertension and Interleukins: Potential Therapeutic Target or Future Diagnostic Marker? *Int J Hypertens*. 2019;3159283. DOI: [10.1155/2019/3159283](https://doi.org/10.1155/2019/3159283)

Tay MZ, Poh CM, Rénia L, et al. The trinity of COVID-19: immunity, inflammation and intervention. *Nat Rev Immunol*. 2020;20:363-374. DOI: [10.1038/s41577-020-0311-8](https://doi.org/10.1038/s41577-020-0311-8)

Teuwen L, Geldhof V, Pasut A, et al. COVID-19: the vasculature unleashed. *Nat Rev Immunol*. 2020. DOI: [10.1038/s41577-020-0343-0](https://doi.org/10.1038/s41577-020-0343-0)

Yingxia Liu, Cong Zhang, Fenming Huang, et al. Elevated plasma level of selective cytokines in COVID-19 patients reflect viral load and lung injury. *National Science Review* 2020;nwaa037. DOI: [10.1093/nsr/nwaa037](https://doi.org/10.1093/nsr/nwaa037)

Zhang C, Wu Z, Li JW, Zhao H, Wang GQ. Cytokine release syndrome in severe COVID-19: interleukin-6 receptor antagonist tocilizumab may be the key to reduce mortality. *Int J Antimicrob Agents* 2020;55(5):105954. DOI: [10.1016/j.ijantimicag.2020.105954](https://doi.org/10.1016/j.ijantimicag.2020.105954)

Visuals by Visual World, Luis Prado, Gan Khoon Lay, Eucalyp and Javier Nuño from the Noun Project. Medical treatment by Visual World. Caring by Luis Prado. Human figure by Javier Nuño. Virus by Gan Khoon Lay. Acute lung by Eucalyp.

Additional Resources

- [Immunology Resources at Bio-Rad-Antibodies.com](#)
- [Immunology Antibodies at Bio-Rad-Antibodies.com](#)

Bio-Plex Multiplex Immunoassays

- [Bio-Plex Pro Human Chemokine Assay](#)
- [Bio-Plex Pro Human Immunology 20-Plex Assay](#)
- [Bio-Plex Pro Human Cytokine 27-Plex Assay](#)
- [Bio-Plex Pro Human Cytokine Screening Panel, 48-Plex Assay](#)

Visit [bio-rad.com/webinars](https://www.bio-rad.com/webinars) for more webinars

Bio-Rad is a trademark of Bio-Rad Laboratories, Inc. in certain jurisdictions. All trademarks used herein are the property of their respective owner.